Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)

Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome

The purpose of this study was to assess the incidence rate of the major adverse cardiovascular events (MACE) and safety of fenofibrate (Lipilfen capsule) add-on statin therapy in patients who have history of acute myocardial infarction and are diagnosed with metabolic syndrome.

Inclusion Criteria:

• patients >20 years of age.
• history of acute myocardial infarction
• metabolic syndrome diagnosis

Exclusion Criteria:

• current liver disease or AST or ALT greater than 3 times the upper limit of reference range
• pre-existing gallbladder disease
• moderate to severe renal disorder (serum creatinine >2.5mg/dL)
• pancreatitis diagnosis